TW202319398A - 抗體配製物 - Google Patents

抗體配製物 Download PDF

Info

Publication number
TW202319398A
TW202319398A TW111130262A TW111130262A TW202319398A TW 202319398 A TW202319398 A TW 202319398A TW 111130262 A TW111130262 A TW 111130262A TW 111130262 A TW111130262 A TW 111130262A TW 202319398 A TW202319398 A TW 202319398A
Authority
TW
Taiwan
Prior art keywords
liquid composition
antibody
seq
buffer
arginine
Prior art date
Application number
TW111130262A
Other languages
English (en)
Chinese (zh)
Inventor
尼可 李 包爾
克里斯多福 詹姆士 斯洛伊
愛樂席思 盧瑞斯
汝麟 錢
Original Assignee
美商安進公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安進公司 filed Critical 美商安進公司
Publication of TW202319398A publication Critical patent/TW202319398A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
TW111130262A 2021-08-12 2022-08-11 抗體配製物 TW202319398A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163232299P 2021-08-12 2021-08-12
US63/232,299 2021-08-12
US202263316604P 2022-03-04 2022-03-04
US63/316,604 2022-03-04

Publications (1)

Publication Number Publication Date
TW202319398A true TW202319398A (zh) 2023-05-16

Family

ID=83151728

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111130262A TW202319398A (zh) 2021-08-12 2022-08-11 抗體配製物

Country Status (16)

Country Link
US (1) US20240343795A1 (enExample)
EP (1) EP4384217A1 (enExample)
JP (1) JP2024532736A (enExample)
KR (1) KR20240046881A (enExample)
AU (1) AU2022325870A1 (enExample)
CA (1) CA3228269A1 (enExample)
CL (1) CL2024000401A1 (enExample)
CO (1) CO2024001383A2 (enExample)
CR (1) CR20240130A (enExample)
IL (1) IL310275A (enExample)
JO (1) JOP20240024A1 (enExample)
MX (1) MX2024001934A (enExample)
PE (1) PE20240650A1 (enExample)
TW (1) TW202319398A (enExample)
UY (1) UY39896A (enExample)
WO (1) WO2023018870A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026062214A1 (en) * 2024-09-19 2026-03-26 Sanofi Formulations comprising lunsekimig

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP2963057A1 (en) 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15
EP3472202A1 (en) 2016-06-15 2019-04-24 Amgen Inc. Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease
EP3824906A1 (en) * 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
PL3615066T3 (pl) 2017-04-28 2024-04-29 Amgen Inc. Formulacje ludzkich przeciwciał anty-RANKL i sposoby ich zastosowania
US12103979B2 (en) * 2017-04-28 2024-10-01 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
MX2020007291A (es) 2018-01-12 2020-09-10 Amgen Inc Anticuerpos anti-pd-1 y metodos de tratamiento.
WO2021079337A1 (en) * 2019-10-23 2021-04-29 Cadila Healthcare Limited Pharmaceutical formulation of anti-her2 antibody and preparation thereof

Also Published As

Publication number Publication date
IL310275A (en) 2024-03-01
WO2023018870A1 (en) 2023-02-16
MX2024001934A (es) 2024-03-04
JOP20240024A1 (ar) 2024-02-08
CA3228269A1 (en) 2023-02-16
US20240343795A1 (en) 2024-10-17
PE20240650A1 (es) 2024-04-04
JP2024532736A (ja) 2024-09-10
KR20240046881A (ko) 2024-04-11
EP4384217A1 (en) 2024-06-19
CO2024001383A2 (es) 2024-03-07
CL2024000401A1 (es) 2024-06-21
AU2022325870A1 (en) 2024-02-08
CR20240130A (es) 2024-04-12
UY39896A (es) 2023-02-28

Similar Documents

Publication Publication Date Title
JP7356525B2 (ja) ヒト抗ｒａｎｋｌ抗体の製剤及びその使用方法
JP7402693B2 (ja) 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法
CN112105343B (zh) 抗-pd-1抗体组合物
TWI733664B (zh) 包含抗ｐｄ１抗體及另一種抗體之組合的組合物
CN104302320B (zh) 冻干以及水性抗cd40抗体制剂
US10689438B2 (en) Stable protein solution formulation containing high concentration of an anti-VEGF antibody
US20240182554A1 (en) Protein solution formulation containing high concentration of an anti-vegf antibody
KR20160055243A (ko) 점도저하제를 함유하는 액체 단백질 제형
CN104220047B (zh) 含有生物治疗剂和胍或胍衍生物的水性药物组合物以及包含所述组合物的注射剂
JP2015536930A (ja) 抗体の高濃度液体製剤の製造方法
CN115243718A (zh) 稳定的抗体制剂
US20240343795A1 (en) Antibody formulations
HK40110344A (en) Antibody formulations
CN117794574A (zh) 抗体配制品
KR20230020449A (ko) 레빌리맙의 수성 약학적 조성물
CA3093036C (en) Anti-pd-1 antibody compositions
TW202541845A (zh) 穩定醫藥製劑
WO2025140467A1 (zh) 稳定的高浓度抗pd-1抗体药物制剂
CA2966758C (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
HK40109865A (en) Stable anti-osmr antibody formulation
EA045933B1 (ru) Водная фармацевтическая композиция левилимаба и ее применение
HK40041199A (en) Anti-pd-1 antibody compositions
JP2023532203A (ja) アクチビンａ抗体製剤及びその使用方法
BR112017021688B1 (pt) Composição farmacêutica e kit da mesma
BR122025004506A2 (pt) Composições farmacêuticas compreendendo uma combinação de um anticorpo anti-pd-1 e outro anticorpo, método de preparação e usos das mesmas, bem como kit